Robert Baltera Jr., Director at PALISADE BIO, INC. (PALI), bought 30,000 shares at $1.98 ($59K) on 2026-07-01, disclosed to the SEC on 2026-07-06.
Director Robert Baltera Jr. purchased 20,000 shares at $1.98, marking the largest insider purchase in the company's history. This significant vote of confidence arrives as the stock has rallied 161% over the past year despite trading 28% below its 52-week high.
The stock is currently trading at $1.895, representing a 161.38% gain over the last 12 months but still sitting 28.22% below its 52-week high of $2.64.
The FDA clearance for the Investigational New Drug application for PALI-2108 (ulcerative colitis) on June 29, 2026, is a primary catalyst, alongside the fact that this trade represents the largest insider purchase in the company's history.
The stock carries significant risk with a short interest of 18.16% of the float, and the company reported R&D expenses of $6.4 million in Q1 2026, which is six times higher than the prior year.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $1.98 | 20,000 | $40K | 66.7% |
| 2 | $1.98 | 10,000 | $20K | 33.3% |
| Total | $1.98 avg | 30,000 | $59K | 100% |
| Filing → |
| IMGO | BUY | 2021-07-19 | $14K | — | Filing → |
| ONVO | SELL | 2015-09-23 | $24K | — | Filing → |